Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating Cells

Walter Koch's Biography

Walter Koch, Vice President, Roche Molecular Systems

Walter H. Koch, Ph.D., has been in his current role of Vice President and Head of Global Research for Roche Molecular Systems since 2005. Dr. Koch is responsible for all RMD research and early development activities, including research efforts associated with biomarker discovery and validation, the development of new technologies with diagnostics potential such as next generation sequencing, and continuing improvements in the performance of existing real time PCR products and technologies. He joined RMS in 1998 as a Research Leader to evaluate the feasibility of developing microarray-based pharmacogenetic assays for clinical diagnostic use, resulting in the launch of the AmpliChip® CYP450 assay. From 2001-2004 he served as the Senior Director of the Pharmacogenetics Department, leading six scientific teams. In this role, he was responsible for development of genetic and pharmacogenomic assays using Affymetrix oligonucleotide microarray, linear array, and real-time PCR technologies and platforms. Prior to joining Roche he held several positions within the US FDA, including Acting Lab Chief of Immunochemistry and Research Biologist in the CBER’s Division of Transfusion Transmitted Disease, and Research Biologist positions in the Division of Molecular Biological Research & Evaluation, and the Division of Toxicology within CFSAN. He received a B.S. in Chemistry from Memphis State University, a Ph.D. in Toxicology and Pharmacology from the University of Tennessee Health Science Center, and Postdoctoral training at the Johns Hopkins University School of Public Health.

Walter Koch Image

Blood-based Testing for Somatic Alterations in Non-Small Cell Lung Cancer

Monday, 20 March 2017 at 09:00

Add to Calendar ▼2017-03-20 09:00:002017-03-20 10:00:00Europe/LondonBlood-based Testing for Somatic Alterations in Non-Small Cell Lung

For cancer patients with inaccessible or unavailable tumor tissue biopsies, an unmet Medical need exists for a surrogate for tissue testing.   New ultra-sensitive PCR and NGS technologies allow analysis of tumor derived nucleic acids and cells in blood with potential applications to therapy selection for targeted therapeutics, assessment of initial therapy response, monitoring for disease progression during treatment, and identification of drug resistance mechanisms that can suggest further treatment options.  This presentation will cover clinical development of a FDA approved assay detecting EGFR mutations in plasma from NSCLC patients to highlight what is possible, what has been achieved, and what challenges remain before Liquid Biopsy applications find routine clinical use.

Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating